TY - JOUR
T1 - Determination of creatine kinase isozymes in sera and tissues of patients with various lung carcinomas
AU - Usui, Akihiko
AU - Fujita, Kouichi
AU - Imaizumi, Munehisa
AU - Abe, Toshio
AU - Inoue, Kouji
AU - Matumoto, Shuuichi
AU - Kato, Kanefusa
PY - 1987/4/15
Y1 - 1987/4/15
N2 - Three creatine kinase isozymes (CK-BB, CK-MB and CK-MM) were estimated by immunoassay in tumor tissues and in sera of patients with various lung carcinomas. CK-BB was increased in small cell carcinoma, but not in other lung carcinomas. CK-MM and CK-MB were not increased in any types of carcinoma. Serum CK-BB was increased in all types of lung carcinoma examined, while serum CK-MM and CK-MB were within normal limits in all patients. Serum CK-BB of healthy adults was estimated as 0.32 ± 0.14 (mean ± SD) ng/ml, ranging from 0.11-0.68 ng/ml. If CK-BB values above 1.0 ng/ml were considered abnormal, elevation occurred in 28/40 (70%) of patients with small cell carcinoma, 25/67 (37%) with adenocarcinoma, 21/51 (41%) with squamous cell carcinoma, 4/11 (36%) with other carcinoma of the lung and 10/42 (24%) with lung tuberculosis. Since serum CK-BB with lung cancer changed in parallel with the clinical course, this isozyme may be a marker for monitoring the clinical course, especially in small cell carcinoma of the lung.
AB - Three creatine kinase isozymes (CK-BB, CK-MB and CK-MM) were estimated by immunoassay in tumor tissues and in sera of patients with various lung carcinomas. CK-BB was increased in small cell carcinoma, but not in other lung carcinomas. CK-MM and CK-MB were not increased in any types of carcinoma. Serum CK-BB was increased in all types of lung carcinoma examined, while serum CK-MM and CK-MB were within normal limits in all patients. Serum CK-BB of healthy adults was estimated as 0.32 ± 0.14 (mean ± SD) ng/ml, ranging from 0.11-0.68 ng/ml. If CK-BB values above 1.0 ng/ml were considered abnormal, elevation occurred in 28/40 (70%) of patients with small cell carcinoma, 25/67 (37%) with adenocarcinoma, 21/51 (41%) with squamous cell carcinoma, 4/11 (36%) with other carcinoma of the lung and 10/42 (24%) with lung tuberculosis. Since serum CK-BB with lung cancer changed in parallel with the clinical course, this isozyme may be a marker for monitoring the clinical course, especially in small cell carcinoma of the lung.
UR - http://www.scopus.com/inward/record.url?scp=0023241302&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0023241302&partnerID=8YFLogxK
U2 - 10.1016/0009-8981(87)90106-9
DO - 10.1016/0009-8981(87)90106-9
M3 - Article
C2 - 3034455
AN - SCOPUS:0023241302
SN - 0009-8981
VL - 164
SP - 47
EP - 53
JO - Clinica Chimica Acta
JF - Clinica Chimica Acta
IS - 1
ER -
